He added that mRNA vaccine technology, made famous during the Covid-19 pandemic, has a major role in future therapies and is "actually at the heart" of breakthrough therapies like Spinraza and Qalsody ...

Cartesian Therapeutics, Inc. ( ($RNAC) ) has released its Q3 earnings. Here is a breakdown of the information Cartesian ...

When it comes to selecting Cabinet members for President-elect Donald Trump's second term, you can't have too much of a good thing.

PHILADELPHIA — The same technology that saved millions of lives during the COVID-19 pandemic appears to hold promise against another scourge of infectious disease, according to new research from the ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

The optimal time to get your seasonal flu shot, according to the Food and Drug Administration (FDA), is right now: flu ...

Barclays lowered the firm’s price target on Moderna (MRNA) to $111 from $125 and keeps an Overweight rating on the shares. The ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

The in vivo cell therapy seed Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. | The in vivo cell ...